Which has preferable valuation & earnings, CYRX or QSI?

CryoPort has higher revenue and earnings than Quantum-Si. CryoPort is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $192.44M 5.24 $78.30M -$0.97 N/A Quantum-Si $2.44M 103.16 -$101.34M -$0.39 N/A

Is CYRX or QSI more profitable?

CryoPort has a net margin of -21.46% compared to Quantum-Si's net margin of -6,729.80%. CryoPort's return on equity of -8.28% beat Quantum-Si's return on equity. Company Net Margins Return on Equity Return on Assets CryoPort -21.46% -8.28% -4.88% Quantum-Si -6,729.80% -44.72% -41.26%

Does the media refer more to CYRX or QSI?

In the previous week, CryoPort had 12 more articles in the media than Quantum-Si. MarketBeat recorded 15 mentions for CryoPort and 3 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.80 beat CryoPort's score of 0.50 indicating that Quantum-Si is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Quantum-Si 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer QSI or PACB?

In the previous week, Pacific Biosciences of California had 7 more articles in the media than Quantum-Si. MarketBeat recorded 10 mentions for Pacific Biosciences of California and 3 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.80 beat Pacific Biosciences of California's score of 0.37 indicating that Quantum-Si is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum-Si 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacific Biosciences of California 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DNA or QSI more profitable?

Ginkgo Bioworks has a net margin of -249.20% compared to Quantum-Si's net margin of -6,729.80%. Quantum-Si's return on equity of -44.72% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -249.20% -56.97% -24.60% Quantum-Si -6,729.80% -44.72% -41.26%

Does the media favor DNA or QSI?

In the previous week, Ginkgo Bioworks had 4 more articles in the media than Quantum-Si. MarketBeat recorded 7 mentions for Ginkgo Bioworks and 3 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.80 beat Ginkgo Bioworks' score of -0.17 indicating that Quantum-Si is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Quantum-Si 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CTKB or QSI?

In the previous week, Cytek Biosciences had 3 more articles in the media than Quantum-Si. MarketBeat recorded 6 mentions for Cytek Biosciences and 3 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.80 beat Cytek Biosciences' score of 0.57 indicating that Quantum-Si is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum-Si 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, QSI or OABI?

OmniAb has higher revenue and earnings than Quantum-Si. OmniAb is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum-Si $2.44M 103.16 -$101.34M -$0.39 N/A OmniAb $18.67M 38.36 -$64.78M -$0.34 N/A

Is QSI or OABI more profitable?

OmniAb has a net margin of -108.11% compared to Quantum-Si's net margin of -6,729.80%. OmniAb's return on equity of -16.74% beat Quantum-Si's return on equity. Company Net Margins Return on Equity Return on Assets Quantum-Si -6,729.80% -44.72% -41.26% OmniAb -108.11% -16.74% -14.79%

Does the media prefer QSI or OABI?

In the previous week, Quantum-Si and Quantum-Si both had 3 articles in the media. Quantum-Si's average media sentiment score of 0.80 beat OmniAb's score of 0.61 indicating that Quantum-Si is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum-Si 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Quantum-Si (QSI) Competitors

$1.15 -0.07 (-5.74%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$1.16 +0.01 (+1.22%)

As of 11/13/2026 07:59 PM Eastern

Compare

QSI vs. CYRX, PACB, DNA, CTKB, and OABI

Should you buy Quantum-Si stock or one of its competitors? Quantum-Si's main competitors and comparable companies include CryoPort (CYRX), Pacific Biosciences of California (PACB), Ginkgo Bioworks (DNA), Cytek Biosciences (CTKB), and OmniAb (OABI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Quantum-Si compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 39.9% of Quantum-Si shares are owned by institutional investors. 9.5% of CryoPort shares are owned by insiders. Comparatively, 22.0% of Quantum-Si shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, CryoPort had 12 more articles in the media than Quantum-Si. MarketBeat recorded 15 mentions for CryoPort and 3 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.80 beat CryoPort's score of 0.50 indicating that Quantum-Si is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Quantum-Si	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort has a net margin of -21.46% compared to Quantum-Si's net margin of -6,729.80%. CryoPort's return on equity of -8.28% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-21.46%	-8.28%	-4.88%
Quantum-Si	-6,729.80%	-44.72%	-41.26%

CryoPort has higher revenue and earnings than Quantum-Si. CryoPort is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$192.44M	5.24	$78.30M	-$0.97	N/A
Quantum-Si	$2.44M	103.16	-$101.34M	-$0.39	N/A

CryoPort has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.26, indicating that its stock price is 226% more volatile than the broader market.

CryoPort presently has a consensus price target of $21.69, indicating a potential upside of 9.04%. Quantum-Si has a consensus price target of $2.50, indicating a potential upside of 117.39%. Given Quantum-Si's higher probable upside, analysts clearly believe Quantum-Si is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

CryoPort beats Quantum-Si on 9 of the 16 factors compared between the two stocks.

How does Quantum-Si compare to Pacific Biosciences of California?

Quantum-Si (NASDAQ:QSI) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Quantum-Si currently has a consensus target price of $2.50, indicating a potential upside of 117.39%. Pacific Biosciences of California has a consensus target price of $2.57, indicating a potential upside of 30.95%. Given Quantum-Si's stronger consensus rating and higher probable upside, equities research analysts plainly believe Quantum-Si is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Quantum-Si has a beta of 3.26, suggesting that its share price is 226% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

In the previous week, Pacific Biosciences of California had 7 more articles in the media than Quantum-Si. MarketBeat recorded 10 mentions for Pacific Biosciences of California and 3 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.80 beat Pacific Biosciences of California's score of 0.37 indicating that Quantum-Si is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum-Si	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacific Biosciences of California	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

39.9% of Quantum-Si shares are owned by institutional investors. 22.0% of Quantum-Si shares are owned by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Quantum-Si has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum-Si	$2.44M	103.16	-$101.34M	-$0.39	N/A
Pacific Biosciences of California	$160.01M	3.83	-$546.38M	-$0.42	N/A

Pacific Biosciences of California has a net margin of -81.31% compared to Quantum-Si's net margin of -6,729.80%. Quantum-Si's return on equity of -44.72% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum-Si	-6,729.80%	-44.72%	-41.26%
Pacific Biosciences of California	-81.31%	-5,752.12%	-19.52%

Summary

Quantum-Si beats Pacific Biosciences of California on 12 of the 16 factors compared between the two stocks.

How does Quantum-Si compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Quantum-Si has lower revenue, but higher earnings than Ginkgo Bioworks. Quantum-Si is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.80	-$312.76M	-$4.20	N/A
Quantum-Si	$2.44M	103.16	-$101.34M	-$0.39	N/A

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 22.0% of Quantum-Si shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ginkgo Bioworks currently has a consensus price target of $7.00, suggesting a potential downside of 27.11%. Quantum-Si has a consensus price target of $2.50, suggesting a potential upside of 117.39%. Given Quantum-Si's stronger consensus rating and higher possible upside, analysts plainly believe Quantum-Si is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Ginkgo Bioworks had 4 more articles in the media than Quantum-Si. MarketBeat recorded 7 mentions for Ginkgo Bioworks and 3 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.80 beat Ginkgo Bioworks' score of -0.17 indicating that Quantum-Si is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Quantum-Si	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ginkgo Bioworks has a net margin of -249.20% compared to Quantum-Si's net margin of -6,729.80%. Quantum-Si's return on equity of -44.72% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-249.20%	-56.97%	-24.60%
Quantum-Si	-6,729.80%	-44.72%	-41.26%

Ginkgo Bioworks has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.26, meaning that its stock price is 226% more volatile than the broader market.

Summary

Quantum-Si beats Ginkgo Bioworks on 10 of the 16 factors compared between the two stocks.

How does Quantum-Si compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by insiders. Comparatively, 22.0% of Quantum-Si shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Cytek Biosciences had 3 more articles in the media than Quantum-Si. MarketBeat recorded 6 mentions for Cytek Biosciences and 3 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.80 beat Cytek Biosciences' score of 0.57 indicating that Quantum-Si is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum-Si	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytek Biosciences has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.26, meaning that its share price is 226% more volatile than the broader market.

Cytek Biosciences presently has a consensus target price of $5.67, suggesting a potential downside of 2.97%. Quantum-Si has a consensus target price of $2.50, suggesting a potential upside of 117.39%. Given Quantum-Si's stronger consensus rating and higher probable upside, analysts clearly believe Quantum-Si is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Cytek Biosciences has a net margin of -39.10% compared to Quantum-Si's net margin of -6,729.80%. Cytek Biosciences' return on equity of -13.13% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-39.10%	-13.13%	-9.56%
Quantum-Si	-6,729.80%	-44.72%	-41.26%

Cytek Biosciences has higher revenue and earnings than Quantum-Si. Cytek Biosciences is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.79	-$66.54M	-$0.63	N/A
Quantum-Si	$2.44M	103.16	-$101.34M	-$0.39	N/A

Summary

Quantum-Si beats Cytek Biosciences on 9 of the 16 factors compared between the two stocks.

How does Quantum-Si compare to OmniAb?

Quantum-Si (NASDAQ:QSI) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Quantum-Si currently has a consensus price target of $2.50, suggesting a potential upside of 117.39%. OmniAb has a consensus price target of $11.50, suggesting a potential upside of 134.22%. Given OmniAb's stronger consensus rating and higher possible upside, analysts clearly believe OmniAb is more favorable than Quantum-Si.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
OmniAb	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Quantum-Si has a beta of 3.26, suggesting that its stock price is 226% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

OmniAb has higher revenue and earnings than Quantum-Si. OmniAb is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum-Si	$2.44M	103.16	-$101.34M	-$0.39	N/A
OmniAb	$18.67M	38.36	-$64.78M	-$0.34	N/A

In the previous week, Quantum-Si and Quantum-Si both had 3 articles in the media. Quantum-Si's average media sentiment score of 0.80 beat OmniAb's score of 0.61 indicating that Quantum-Si is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum-Si	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OmniAb has a net margin of -108.11% compared to Quantum-Si's net margin of -6,729.80%. OmniAb's return on equity of -16.74% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum-Si	-6,729.80%	-44.72%	-41.26%
OmniAb	-108.11%	-16.74%	-14.79%

39.9% of Quantum-Si shares are held by institutional investors. Comparatively, 72.1% of OmniAb shares are held by institutional investors. 22.0% of Quantum-Si shares are held by insiders. Comparatively, 9.8% of OmniAb shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

OmniAb beats Quantum-Si on 9 of the 14 factors compared between the two stocks.

Get Quantum-Si News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QSI vs. The Competition

Export

Metric	Quantum-Si	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$267.04M	$11.03B	$7.84B	$12.19B
Dividend Yield	N/A	1.45%	2.46%	4.53%
P/E Ratio	-2.95	56.52	34.71	28.44
Price / Sales	103.16	7.22	8.66	5.84
Price / Cash	N/A	26.69	21.93	22.49
Price / Book	1.58	4.59	4.35	3.76
Net Income	-$101.34M	$57.48B	$3.51B	$390.55M
7 Day Performance	-13.53%	-0.41%	-1.49%	-0.33%
1 Month Performance	-17.27%	1.11%	-2.55%	-4.82%
1 Year Performance	-16.06%	21.45%	0.92%	-5.83%

Quantum-Si Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QSI Quantum-Si	3.5196 of 5 stars	$1.15 -5.7%	$2.50 +117.4%	-17.3%	$267.04M	$2.44M	N/A	145	Analyst Forecast
CYRX CryoPort	1.8848 of 5 stars	$20.47 +7.2%	$21.69 +5.9%	+127.1%	$845.84M	$176.18M	N/A	738	News Coverage Insider Trade Analyst Revision High Trading Volume
PACB Pacific Biosciences of California	2.0026 of 5 stars	$2.36 +4.4%	$2.43 +2.8%	+20.2%	$792.62M	$160.01M	N/A	485
DNA Ginkgo Bioworks	1.1554 of 5 stars	$12.37 +9.6%	$7.00 -43.4%	+19.8%	$784.51M	$170.15M	N/A	485	Gap Down
CTKB Cytek Biosciences	1.7048 of 5 stars	$5.89 +1.0%	$5.88 -0.3%	+27.8%	$764.30M	$201.49M	N/A	702	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QSI) was last updated on 11/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quantum-Si (QSI) Competitors

QSI vs. CYRX, PACB, DNA, CTKB, and OABI

How does Quantum-Si compare to CryoPort?

Summary

How does Quantum-Si compare to Pacific Biosciences of California?

Summary

How does Quantum-Si compare to Ginkgo Bioworks?

Summary

How does Quantum-Si compare to Cytek Biosciences?

Summary

How does Quantum-Si compare to OmniAb?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QSI vs. The Competition

Quantum-Si Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quantum-Si (QSI) Competitors

QSI vs. CYRX, PACB, DNA, CTKB, and OABI

How does Quantum-Si compare to CryoPort?

Do insiders & institutionals have more ownership in CYRX or QSI?

Does the media refer more to CYRX or QSI?

Is CYRX or QSI more profitable?

Which has preferable valuation & earnings, CYRX or QSI?

Which has more volatility & risk, CYRX or QSI?

Do analysts rate CYRX or QSI?

Summary

How does Quantum-Si compare to Pacific Biosciences of California?

Do analysts rate QSI or PACB?

Which has more risk and volatility, QSI or PACB?

Does the media prefer QSI or PACB?

Do insiders and institutionals have more ownership in QSI or PACB?

Which has stronger earnings and valuation, QSI or PACB?

Is QSI or PACB more profitable?

Summary

How does Quantum-Si compare to Ginkgo Bioworks?

Which has preferable earnings & valuation, DNA or QSI?

Do institutionals & insiders hold more shares of DNA or QSI?

Do analysts rate DNA or QSI?

Does the media favor DNA or QSI?

Is DNA or QSI more profitable?

Which has more volatility and risk, DNA or QSI?

Summary

How does Quantum-Si compare to Cytek Biosciences?

Do institutionals and insiders hold more shares of CTKB or QSI?

Does the media refer more to CTKB or QSI?

Which has more risk & volatility, CTKB or QSI?

Do analysts rate CTKB or QSI?

Is CTKB or QSI more profitable?

Which has stronger valuation & earnings, CTKB or QSI?

Summary

How does Quantum-Si compare to OmniAb?

Do analysts recommend QSI or OABI?

Which has more risk and volatility, QSI or OABI?

Which has preferable valuation and earnings, QSI or OABI?

Does the media prefer QSI or OABI?

Is QSI or OABI more profitable?

Do insiders and institutionals hold more shares of QSI or OABI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QSI vs. The Competition

Quantum-Si Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools